Abstract CT139: The STELLAR trial: A phase II/III study of high-dose intermittent sunitinib in patients with recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct139
Abstract: Background: Treatment options for patients with recurrent glioblastoma (rGBM) are limited. The lack of effectiveness from oral multi-targeted tyrosine kinase inhibitors, like sunitinib, might be due to a restricted blood-brain barrier penetration. We previously found… read more here.
Keywords: sunitinib; intermittent sunitinib; trial; high dose ... See more keywords
Determinants of uptake of first dose of intermittent preventive treatment among pregnant women in a secondary health Centre in Maiduguri, Nigeria
Sign Up to like & getrecommendations! Published in 2020 at "BMC Pregnancy and Childbirth"
DOI: 10.1186/s12884-020-03388-8
Abstract: Background Studies on uptake of first dose of intermittent preventive treatment in pregnancy (IPTp) are lacking, despite it being a predictor of subsequent doses. This study aimed at assessing the determinants of uptake of first… read more here.
Keywords: first dose; dose intermittent; pregnant women; iptp ... See more keywords
High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14246061
Abstract: Simple Summary Multitargeted tyrosine kinase inhibitors (TKIs) provide clinical benefit in patients with cancer when daily dosed to continuously inhibit their designated targets. Alternative dosing strategies pursuing higher tumor drug concentrations may improve their benefit… read more here.
Keywords: tumor drug; high dose; treatment; tumor ... See more keywords